{
  "completed": true,
  "status": "documented_historical_discovery_and_reconciliation",
  "provider": "Consensus",
  "provider_mode": "Historical browser/connector use as recorded in the source artifacts",
  "local_audit_date": "2026-10-09",
  "primary_comparison_count": null,
  "reported_usage": [],
  "grade_changed": false,
  "score_before": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "Substantial multi-modal primary literature with many full texts read supports the distinction between efficacy and mechanism. Human measurement is heterogeneous, mediator identification is absent, several records remain access-limited, and the largest randomized datasets are not yet peer reviewed and carry no part of the grade. This is evidence-density confidence, not a probability that the hypothesis is true.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "SC1 protocol-level clinical response and SC3 adult experimental cortical effects reach Ε; approximately twelve-week persistence is a qualified Δ. The temporary human cortical-plasticity interval and its causal contribution to sustained symptoms each remain Γ under rubric 07's acute-pharmacodynamic and mediation-by-correlation rules. Weakest-link therefore returns Γ. The red-team pass changed neither the overall letter nor any subclaim level.",
    "non_peer_reviewed_note": "Company and regulatory documents describing the phase 3 program (COMP005, COMP006) are reported as context only. Under the framework source-tier rule they are inadmissible as evidence items, hold no ledger row, and carry no part of the grade or confidence band."
  },
  "score_after": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "Substantial multi-modal primary literature with many full texts read supports the distinction between efficacy and mechanism. Human measurement is heterogeneous, mediator identification is absent, several records remain access-limited, and the largest randomized datasets are not yet peer reviewed and carry no part of the grade. This is evidence-density confidence, not a probability that the hypothesis is true.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "SC1 protocol-level clinical response and SC3 adult experimental cortical effects reach Ε; approximately twelve-week persistence is a qualified Δ. The temporary human cortical-plasticity interval and its causal contribution to sustained symptoms each remain Γ under rubric 07's acute-pharmacodynamic and mediation-by-correlation rules. Weakest-link therefore returns Γ. The red-team pass changed neither the overall letter nor any subclaim level.",
    "non_peer_reviewed_note": "Company and regulatory documents describing the phase 3 program (COMP005, COMP006) are reported as context only. Under the framework source-tier rule they are inadmissible as evidence items, hold no ledger row, and carry no part of the grade or confidence band."
  },
  "independent_blinded_audit": false,
  "raw_receipts": [
    {
      "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\psilocybin-therapy\\consensus-browser-links.json",
      "sha256": "9686b2a0d79918a7ae19ca2af42d6e2ff168dc06155c03e3135ad472dd2337b3"
    },
    {
      "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\psilocybin-therapy\\consensus-browser.txt",
      "sha256": "f0af0c5d83f9c40c29c389c96dd332cf0cc8e0224123038e62b46d2d75722085"
    },
    {
      "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\psilocybin-therapy\\consensus-targeted-check.txt",
      "sha256": "62dfee4403421884c433180bdfe53cbacecd36d92e3379c622d6b5cf79d91c14"
    }
  ],
  "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.",
  "existing_primary_reconciliation": {
    "slug": "psilocybin-therapy",
    "consensus_used": true,
    "rawproof": [
      "deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-browser.txt",
      "deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-targeted-check.txt",
      "deliverables/prepublication-enrichment-2026-10-05/website-series/psilocybin-therapy/consensus-browser-links.json"
    ],
    "reconciliation_existing": "Yes; 9 primary identifiers; selected mechanistic Methods/Results passage and caveat about overall nonsignificant SV2A result; correction notice flagged.",
    "primary_sources_matched": [
      "27210031",
      "33852780",
      "34228959",
      "36322843",
      "37651119",
      "40175553",
      "41224969",
      "42138922",
      "42457666"
    ],
    "limitations": "Do not transfer separate psilocybin-dual-phase run; selected mechanistic check does not establish human mediation; 2025 mouse study has correction notice."
  }
}